ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS

ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS

Double anti-platelet therapy (DAPT) comprising a combination of acetylsalicylic acid and one of the thrombocyte P2Y12-receptor blockers is considered an obligatory element of the acute coronary syndrome (ACS) therapy [1–5]. Enlargement of the antiplatelet drugs range with active implementation of ti...

Full description

Bibliographic Details
Main Author:	O. V. AVERKOV
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2016-12-01
Series:	Медицинский совет
Subjects:	acute coronary syndrome anti-platelet drugs p2y12 blockers ticagrelor clopidrogel plato study
Online Access:	https://www.med-sovet.pro/jour/article/view/1411

Similar Items

Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients
by: Manuel Veas Porlán, et al.
Published: (2023-06-01)

Factors Determining Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome
by: Vytenis Tamakauskas, et al.
Published: (2022-10-01)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
by: Lulu Dai, et al.
Published: (2022-06-01)

Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
by: Barry W. Hennigan, et al.
Published: (2022-01-01)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Po-Wei Chen, et al.
Published: (2020-06-01)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
by: Thomas W. Johnson, et al.
Published: (2020-12-01)

Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake
by: Kok Weng Ow, et al.
Published: (2020-10-01)

Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study)
by: Meijiao He, et al.
Published: (2022-11-01)

The Effect of Platelet Activity, ABCB1 Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome
by: Tamakauskas V, et al.
Published: (2024-01-01)

Analysis of ticagrelor’s cardio-protective effects on patients with ST-segment elevation acute coronary syndrome accompanied with diabetes
by: Li Dong-Tao, et al.
Published: (2019-02-01)

Thrombocyte aggregation activity in the conditions of intensive light deprivation
by: V. F. Kirichuk, et al.
Published: (2020-07-01)

Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy
by: Thomas A. Nelson, et al.
Published: (2022-04-01)

A Case Report of Ticagrelor-Induced Thrombocytopenia
by: Alsalman M
Published: (2023-07-01)

Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial
by: Laeun Kim, et al.
Published: (2021-03-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
by: Joseph M. Sweeny, et al.
Published: (2017-04-01)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
by: Ana Lucrecia Marcano, et al.
Published: (2022-11-01)

Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane
by: Vahideh Rabani, et al.
Published: (2018-10-01)

Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment
by: Xi Zhang, et al.
Published: (2022-03-01)

Thrombocyte Alterations in Pregnant Women with Gestational Diabetes Mellitus
by: Senol Senturk, et al.
Published: (2018-04-01)

Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial
by: Jae Young Cho, et al.
Published: (2023-08-01)

ANTIPLATELET TREATMENT IN ST ELEVATION ACUTE CORONARY SYNDROME UNDER REAL CLINICAL CIRCUMSTANCES: THE DYNAMICS OF THROMBOCYTE FUNCTION
by: L. I. Malinova, et al.
Published: (2017-02-01)

Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?
by: Peter Blaško, et al.
Published: (2022-12-01)

SOME THROMBOCYTE FACTORS DEVELOPMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C
by: N. Y. Pshenichnaya, et al.
Published: (2013-03-01)

Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran
by: Amir Hashemi-meshkini, et al.
Published: (2023-04-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
by: Yue Wang, et al.
Published: (2022-02-01)

Ticagrelor hemorrhagic safety in patients with acute coronary syndrome with ST-segment elevation received thrombolytic therapy in daily clinical practice: 30-day observation results
by: A. V. Bocharov, et al.
Published: (2020-05-01)

Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention
by: Chenggang Wang, et al.
Published: (2020-04-01)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
by: Mustafa Yildirim, et al.
Published: (2023-08-01)

Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease
by: Meijiao He, et al.
Published: (2019-08-01)

The Immunological Capacity of Thrombocytes
by: Farzana Ferdous, et al.
Published: (2023-08-01)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-02-01)

Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR)
by: Jing Shi, et al.
Published: (2021-01-01)

Comparison of clopidogrel and ticagrelor in treating acute coronary syndrome undergoing PCI: A systematic review and meta-analysis
by: Jing Yang, et al.
Published: (2024-03-01)

Reversal of Platelet Inhibition in Patients Receiving Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-09-01)

Progress in the clinical effects and adverse reactions of ticagrelor
by: Peng Wei, et al.
Published: (2024-01-01)

In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention
by: Aaron E. Brice, et al.
Published: (2017-04-01)

Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: A meta-analysis
by: He Meijiao, et al.
Published: (2022-02-01)

Numerical Modeling of Thrombocyte Interaction Mechanics with a Blood Vessel Wall
by: Raimondas Jasevičius
Published: (2023-11-01)